-Trial to Examine New Therapeutic Platform in Patients with Cystoid Macular
SUNNYVALE, Calif., Aug. 5 /PRNewswire/ -- Icon Bioscience, Inc., (IBI), a privately held ophthalmic pharmaceutical company, announced today that enrollment has been completed in its Phase I clinical trial to assess the safety and efficacy of its lead product, IBI-20089, in patients with cystoid macular edema. This multi-site trial enrolled patients with cystoid macular edema associated with retinal vein occlusion and post operative cataract surgery.
IBI-20089 is a novel drug product based on IBI's proprietary Verisome(TM) drug delivery platform technology, which is optimally suited for application in the ophthalmic market. IBI-20089 is designed to last up to one year with a single intravitreal injection. It uniquely provides physicians the flexibility to tailor the duration of effect for a particular patient. IBI- 20089 is administered as a standard intravitreal injection without the need for additional devices or surgical procedures.
"We are pleased to have reached this important milestone. Our preliminary data confirms the safety and efficacy of our lead product, IBI-20089, as well as the versatility and flexibility of our underlying Verisome(TM) drug delivery technology," said Vernon G. Wong, MD, Founder of Icon Bioscience, Inc. "We believe IBI is creating the future standard of ophthalmic care as evidenced by the development of IBI-20089, the first of many products already in development based on the Verisome(TM) technology."
About Icon Bioscience, Inc.
Icon Bioscience, Inc. (IBI) is a privately held company focused on the
development and commercialization of novel ophthalmic pharmaceuticals,
based on its proprietary Verisome(TM) drug delivery platform. The
Verisome(TM) drug delivery technology encompasses over twenty related but
distinct novel and proprietary drug delivery systems optimally suited for
application in the ophthalmic market. The nature of ophthalmic disease and
the unique anatomical and physiological features of the eye, combined with
the extreme fragility of the eye, dictate that identifying the correct
pharmaceutical agent for a specific disease state represents only half the
solution. The pharmaceutical agent must be delivered in a manner that
maximizes clinical efficacy while minimizing costs and adverse effects.
IBI's lead product, IBI-20089, is in Phase I clinical trials for the
treatment of cystoid macular edema.
Contact: Icon Bioscience, Inc.
William S. (Sandy) White
Phone: 408-734-8188 Ext. 14
|SOURCE Icon Bioscience, Inc.|
Copyright©2008 PR Newswire.
All rights reserved